TLDRs;
- Axsome’s stock surges nearly 23% after the FDA assigns an April PDUFA deadline for the review of AXS-05.
- AXS-05 is seeking approval to treat agitation in Alzheimer’s, with the potential to compete against existing therapies.
- Analysts raise Axsome’s target price to $217, pointing to regulatory progress and a strong pipeline.
- Investors are tracking FDA timelines, commercial performance, and macro trends for future growth.
Axsome Therapeutics (NASDAQ: AXSM) experienced a nearly 23% jump in its share price following the U.S. Food and Drug Administration (FDA) granting priority review to the company’s supplemental new drug application (sNDA) for AXS-05, which is intended to treat agitation in Alzheimer’s disease.
After the FDA established an April 30, 2026 Prescription Drug User Fee Act (PDUFA) date, investors reacted positively to the faster timeline, showing optimism about the therapy’s potential market influence.
On Wednesday, the stock traded between $148.79 and $184.40, closing at $182.64 with a volume of around 3.1 million shares—even though U.S. markets were closed Thursday for New Year’s Day.
AXS-05 Targets Unmet Alzheimer’s Need
AXS-05, a combination of dextromethorphan and bupropion, is already sold under the brand name Auvelity for major depressive disorder.
The filing for Alzheimer’s agitation marks a strategic expansion of its current portfolio. According to Axsome CEO Herriot Tabuteau, agitation affects up to 76% of Alzheimer’s patients, underscoring the urgent need for a treatment.
If approved, AXS-05 would directly compete with Rexulti, which received approval in 2023 as the first therapy for agitation in dementia linked to Alzheimer’s disease.
Analysts Raise Price Targets
The regulatory news led to a significant increase in analyst confidence. Graig Suvannavejh from Mizuho raised Axsome’s price target from $202 to $217 while maintaining an Outperform rating.
The recommendation reflects greater faith in the company’s chances of regulatory success and the commercial potential of AXS-05.
Investors are also keeping an eye on the company’s experimental therapy AXS-12, developed to treat cataplexy in narcolepsy. It has orphan drug status and could qualify for market exclusivity if approved. A submission of AXS-12’s new drug application is expected in January 2026, adding another growth driver for Axsome’s pipeline.
Explosive growth seen in Axsome Therapeutics stock today. Intriguing biomedical sector vibes.
Company Name: Axsome Therapeutics
Symbol:
Price: 182.64
Volume: 3,052,560
% Up: 128%— Stock Market Genius (@stockmktgenius)
Market and Investor Focus Ahead
Looking ahead, traders are monitoring if Axsome adheres to the April review schedule and the outcome of the AXS-12 submission.
The commercial performance of the company’s existing products, such as Auvelity and Symbravo, will also shape investor sentiment—since cash burn and payer coverage remain key factors in assessing biotech risk. Broader macroeconomic trends, including changes in U.S. yields and upcoming employment data, could further impact growth-stock valuations like Axsome’s.
With the next earnings report expected around February 17, 2026, investors will look for updates on spending priorities, product demand, and guidance for regulatory investments.
The jump in Axsome’s shares highlights how sensitive biotech stocks are to regulatory news. The FDA’s accelerated review not only signals potential short-term value for AXS-05 but also boosts confidence in the company’s wider pipeline. As U.S. equity markets reopen, attention will shift to whether the stock can sustain its gains—balancing optimism about regulatory milestones with careful consideration of market conditions and commercial execution.
